menu

ReachMD

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Studying the Safety of Discontinuing DMTs in MS Older Adults

ReachMD Healthcare Image
Restart
Resume
Choose a format
Media formats available:
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.
Details
Presenters
Comments
  • Overview

    Disease-modifying therapies (DMTs) reduce disease activity and slow the progression of disability in multiple sclerosis. But there were some challenges that came out of this recent study. To discuss the findings from this trial, Dr. Andrew Wilner is joined by Dr. John Corboy, Professor of Neurology and the Director of the Rocky Mountain MS Center at the University of Colorado. 

Facebook Comments

Recommended
Details
Presenters
Comments
  • Overview

    Disease-modifying therapies (DMTs) reduce disease activity and slow the progression of disability in multiple sclerosis. But there were some challenges that came out of this recent study. To discuss the findings from this trial, Dr. Andrew Wilner is joined by Dr. John Corboy, Professor of Neurology and the Director of the Rocky Mountain MS Center at the University of Colorado. 

Facebook Comments

Schedule15 Jun 2024